PCC 2.22% 22.0¢ probiomics limited

bioshares report, page-2

  1. 11,729 Posts.
    lightbulb Created with Sketch. 1698
    Mentioned in the oz too:

    Biotechs chalk up a healthy charge
    Probiomics (PCC) 22.5c

    AFTER a lean quarter for biotech capital raisings, global investor interest has surged and we can expect those with a half-decent yarn to replenish the well.
    According to newsletter Bioshares, biotechs raised $12.6 million in the March quarter, compared with $232m in the December quarter. As our Roman envoy would say, that's about enough for a sandwich and a milkshake.
    Paradoxically, biotechs' shares outperformed the broader market in the March quarter. Bioshares estimates a 9 per cent gain while rival Biotech Daily's basket of 40 biotechs surged 16 per cent.
    Having backdoor listed through Probiomics, Hunter Immunology yesterday relisted at a similar level to the $2.2m raised via the restructure. We'll call that a seal of approval for the new entity's quest to commercialise its proposed drug to prevent infections related to chronic obstructive pulmonary disease.
    A phase 2A trial of 38 patients showed that Hunter's lead compound, HI-1640V, reduced hospitalisation by 80 per cent. A phase 2B trial hopes to replicate this with a pool of 320 patients.
    While drug developers tend to promise the world and then deliver the equivalent of Burundi, there's a make-or-break aspect to this one. Chief David Radford says a big pharma is expected after the trial results are released before June 30.
    So those who invested -- including former Colonial First State chief Chris Cuffe and Maple Abbott Brown's Chris Abbott -- will soon know whether this one's a multi-bagger or a tax deduction.
    Probiomic's focus is redolent of that of COPD specialist Pharmaxis (PXS, $1.35), which has cracked the European market for its cystic-fibrosis treatment Bronchitol. It is pitched at improving lung function. We'll call Probiomics a spec buy and also stick with Pharmaxis.

    http://www.hunterimmunology.com/welcome/pdf/The%20Australian%20Finance.pdf
 
watchlist Created with Sketch. Add PCC (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.